查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2150625

胞漿素原原市場報告：趨勢、預測與競爭分析（至2035年）

Plasminogen Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

胞漿素原原市場

受木質性結膜炎、糖尿病足病變和創傷治療等領域的市場機會驅動，全球胞漿素原原市場前景看好。預計到2035年，全球胞漿素原市場規模將從2027年的2.702億美元成長至4.927億美元，2027年至2035年的複合年成長率（CAGR）為39.5%。推動該市場成長的關鍵因素包括對胞漿素原療法的需求不斷成長、血栓性疾病患病率上升以及生物技術研究投資的增加。

  • 根據 Lucintel 的預測，靜脈注射是給藥速度最快的途徑，因此，在預測期內，靜脈注射預計將實現高速成長。
  • 就適應症而言，由於胞漿素原原是目前唯一可用於治療褐煤結膜炎的藥物，因此預計褐煤結膜炎適應症領域在預測期內將呈現最高的成長率。
  • 從區域來看，亞太地區預計將在預測期內呈現最高的成長率，因為隨著診斷率的上升和社會因素的影響，對纖溶酶原療法的需求預計將會增加。

胞漿素原市場的新發展

預計在2025年至2027年間，胞漿素原市場將從目前的替代療法模式轉向其他市場，例如診斷檢測。此外，基於胞漿素原原的生物製藥的生產和分銷預計將會增加。監管機構、醫院進行診斷檢測的能力以及生物製藥公司的投資水準預計將對市場產生影響。 Lucintel也表達了類似的市場觀點。對於基於胞漿素原原的生物製藥而言，臨床數據的有效性和製造商確保生物製藥穩定供應的能力預計將比生產設施的規模更為重要。

  • 早期診斷：預計在2025年至2027年間，將設立專門的先天性胞漿素原原缺乏症診斷中心。此病的發生率為每百萬人1.6例，預計長期治療的需求將會增加。此外，識別高風險患者有望預防對身體組織的進一步損害。
  • 特種生物製藥：在此期間，唯一獲得FDA批准的胞漿素原補充劑Ryplazim預計不會發生重大變化。但是，預計生產商將採取措施提高產品的穩定性和可用性。
  • 重組胞漿素原：多家公司正在研發重組胞漿素原，以減少對捐血的依賴。重組胞漿素原原可能要到2027年後才能商業化，但這項技術可望改善血液供應，並減少對少數幾家公司的依賴。
  • 基於可近性的商業化：保險公司和醫療服務提供者要求提供數據，以證明治療方案如何減少特定手術的需求或如何維持視力。未來，真實世界數據將用於解答這些問題。從2025年開始，保險公司將評估相關證據並調整報銷率。其目標是最佳化支出，從而增加接受治療的患者人數。
  • 專業醫療網路：專業醫療服務提供者之間的合作將變得日益重要。從2025年開始，透過改善遠距醫療和轉診途徑，高風險患者的管理將得到簡化。這將改善偏遠地區患者獲得專業醫療照護和服務的機會。隨著診斷和治療標準的提高，即使在以前服務不足的地區，也能獲得安全的醫療保健。

未來五年，基於胞漿素原原的療法市場將透過識別先前未確診的患者並證明這些療法能夠改善患者的生活品質而發展。加強專業製藥公司、生技公司和診斷試劑生產商之間的教育和合作將有助於提高診斷和治療的可及性。供應的穩定性和可靠性將是供應商之間最重要的差異化因素。

胞漿素原市場近期趨勢

2025年至2027年，胞漿素原市場成長率預計將較為溫和。在此期間，市場活動的主要驅動力預計將來自胞漿素原原相關診斷技術的進步以及罕見疾病血漿替代療法的應用。 Lucintel認為，在此期間，市場發展更受可靠、合格且受監管的生產資源供應的限制，而非頻譜生技藥品的需求水準。

  • 監管整合：2021年，FDA批准了Bioverativ公司的Ryplazim上市，使其成為唯一獲準用於治療遺傳性胞漿素原原缺乏症的藥物。 2025年至2027年間，隨著研發公司將重點放在上市後要求和其他證據上，First-in-Class胞漿素原原製劑的市場機會可能微乎其微甚至完全消失。然而，First-in-Class產品或許能增強醫師對治療患者的信心。
  • 血漿供應：除了擁有龐大且多元化的基本客群以及超過10億歐元的年銷售額外，凱德瑞恩還擁有龐大且穩健的血漿衍生產品生產基礎設施。在同一時期（2025-2027年），其他生物製藥公司也可能投資大規模血漿採集和分離，以滿足日益成長的纖溶酶原產品需求。
  • 診斷：截至2025年，胞漿素原原活性和抗原檢測尚未廣泛應用。提高病例識別能力有助於更早發現胞漿素原缺乏症。預計未來五年內，病例識別和診斷水準將有所提高。
  • 創傷治療：人們對胞漿素原在創傷治療和纖維蛋白溶解中的作用越來越感興趣。預計到2025年，臨床數據將包括100多名先天性纖溶酶原缺乏症患者。雖然這些數據可能為擴大產品適應症奠定基礎，但要實現廣泛應用，可能還需要進行涉及大規模患者的大型臨床試驗。
  • 合作：孤兒藥的生產和商業化正從傳統的基層醫療促銷轉向支持專科療法以及與專科治療中心簽訂分銷協議。 2025年，瑞普拉齊姆（Ryplazim）的體重劑量（6.6 mg/kg）維持不變，給藥仍需專業人員及設施。未來的合作與夥伴關係有望擴大療法的地域覆蓋範圍，並縮短在醫保報銷受限地區啟動治療所需的時間。

在胞漿素原領域建立起顯著的市場地位，例如Kedrion公司以及其他在研項目，將為胞漿素原擺脫目前作為市場替代品的角色奠定基礎。到2030年，胞漿素原的生產和臨床需求將成為市場的主要驅動力。

目錄

第1章：執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章：全球胞漿素原原市場：依類型分類

  • 吸引力分析：按類型
  • 靜脈注射
  • 眼藥水

第5章：全球胞漿素原原市場：依應用分類

  • 吸引力分析：依目的
  • 木質性結膜炎
  • 糖尿病足病變
  • 創傷治療
  • 其他

第6章 區域分析

第7章：北美胞漿素原市場

  • 北美胞漿素原原市場：按類型分類
  • 北美胞漿素原原市場：依應用分類
  • 美國胞漿素原原市場
  • 加拿大胞漿素原原市場
  • 墨西哥胞漿素原原市場

第8章：歐洲胞漿素原市場

  • 歐洲胞漿素原原市場：按類型分類
  • 歐洲胞漿素原原市場：依應用領域分類
  • 德國胞漿素原原市場
  • 法國胞漿素原原市場
  • 義大利胞漿素原原市場
  • 西班牙胞漿素原原市場
  • 英國胞漿素原原市場

第9章：亞太地區的胞漿素原原市場

  • 亞太地區胞漿素原原市場：依類型分類
  • 亞太地區胞漿素原原市場：依應用分類
  • 中國胞漿素原原市場
  • 印度胞漿素原原市場
  • 日本胞漿素原原市場
  • 韓國胞漿素原原市場
  • 印尼胞漿素原原市場

第10章：世界其他地區的胞漿素原原市場

  • 其他地區胞漿素原原市場：依類型分類
  • 其他地區胞漿素原原市場：依應用分類
  • 中東胞漿素原原市場
  • 南美洲胞漿素原原市場
  • 非洲胞漿素原原市場

第11章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第12章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢：全球胞漿素原原市場
  • 戰略分析

第13章：價值鏈中關鍵企業的公司概況

  • 競爭分析概述
  • Kedrion SpA
  • Grifols, SA
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • LFB SA
  • BioProduct Laboratory
  • Green Cross Corp
  • China Biologic Products Holdings, Inc.
  • Hualan Biological Engineering Inc.

第14章附錄

Plasminogen Market

The future of the global plasminogen market looks promising with opportunities in the ligneous conjunctivitis, diabetic foot, and wound healing markets. The global plasminogen market is expected to reach an estimated $492.7 million by 2035 from $270.2 million in 2027 with a CAGR of 39.5% from 2027 to 2035. The major drivers for this market are the increasing demand for plasminogen therapies, the rising prevalence of thrombotic disorders, and the growing investment in biotechnology research.

  • Lucintel forecasts that, within the type category, intravenous injection is expected to witness higher growth over the forecast period due to iv injection provides the fastest route of administration.
  • Within the application category, ligneous conjunctivitis is expected to witness the highest growth over the forecast period due to plasminogen is the only treatment available for ligneous conjunctivitis.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased diagnosis and social factors will lead to greater demand for poblacion treatment.

Emerging Trends in Plasminogen Market

Between 2025 and 2027, the plasminogen market is expected to shift away from the current replacement therapy model and toward other markets, such as diagnostic testing. Additionally, the manufacture and distribution of plasminogen-based biologics is expected to increase. Regulatory agencies, the capacity of hospitals to perform diagnostic testing, and the level of investment by biopharmaceutical companies will influence the market. Lucintel has taken a similar market view. For plasminogen-based biologics, the relevance of clinical data and the ability of the manufacturers to ensure the reliable supply of their biologics is expected to play a greater role as compared to the size of the facilities in which the biologics are manufactured.

  • Earlier Diagnosis: From 2025 to 2027, it is anticipated that specialized testing centers will become available to diagnose congenital deficiencies of plasminogen. With a prevalence of 1.6 cases per million, the demand for long-term treatment is expected to increase. Additionally, the identification of patients at risk is expected to help prevent further damage to body tissues.
  • Specialty Biologics: During the same time frame, it is anticipated that little change will occur with respect to the only FDA-approved plasminogen replacement, Ryplazim. However, it is expected that the sponsoring company will make efforts to improve the stability and usability of the product.
  • Recombinant Plasminogen: Several companies are in the process of developing recombinant forms of plasminogen to reduce reliance on blood donations. While recombinant plasminogen may not be available on a commercial basis until after 2027, the technologies developed may improve the supply and reduce the reliance on a few companies.
  • Access-based Commercialization: Payers and accounts are requesting data that demonstrate how a therapy reduces the need for particular procedures or preserves sight. In the future, real world data will be used to answer these questions. Starting in 2025, payers will evaluate the evidence and adjust reimbursement. The goal will be to optimize spend to increase the number of treated patients.
  • Specialist Care Networks: There will be greater emphasis on coordinating specialty care. Beginning in 2025, management of high risk patients will be facilitated via improved teleconsultation and referral pathways. This will positively impact access to specialized care and services for patients living in remote areas. Greater diagnostic and therapeutic standardization will facilitate safe service delivery in previously unserved areas.

In the next five years, a market will exist for plasminogen based on the ability to identify previously undiagnosed patients and demonstrate the therapy improves patients' quality of life. Access to diagnostics and therapeutics will improve with greater education and collaboration between specialty pharma, biotech and diagnostics manufacturers. Stability and reliability of supply will be the most important factor differentiating suppliers.

Recent Developments in the Plasminogen Market

Rates of change in the plasminogen market are expected to be relatively slow from 2025 to 2027. Advances in plasminogen-related diagnostics and rare-disease plasma replacement therapies are expected to largely drive market activity during this period. Lucintel believes that, during this time frame, market development will be more limited by the availability of reliable, satisfactory, and compliant manufacturing sources than by the prevailing level of demand for broad-spectrum biologics.

  • Regulatory Consolidation: In 2021, the FDA granted marketing authorization to Bioverativ's Ryplazim, thus becoming the only approved treatment for hereditary plasminogen deficiency. Between 2025 and 2027, sponsors will focus on post-market requirements and other evidence, thereby creating little to no market opportunities for first-in class plasminogen products. First-in-class products may, however, improve the confidence of treating physicians.
  • Plasma Supply: In addition to having a large, diversified customer base and an annual revenue exceeding one billion Euros, Kedrion also has a large and robust plasma-derivative manufacturing infrastructure. During the same time frame (2025-2027), other biopharmaceutical companies may also invest in large-scale plasma collection and fractionation to supply the growing demand for plasminogen products.
  • Diagnostics: In 2025, plasminogen activity and antigen testing were not widely available. Improved case identification may lead to earlier recognition of plasminogen deficiency. Case identification and diagnosis are anticipated to improve in the next five years.
  • Wound Healing: Increased interest is directed to the role of plasminogen in healing and fibrinolysis. Clinical data expected by 2025 will support greater than 100 patients with congenital deficiencies. While these data may provide the foundation to expand the product label, clinical studies in larger patient populations will be needed prior to broad adoption.
  • Partnerships: Manufacturing and commercialization of treatments for rare diseases have shifted to sponsorship of specialty treatment and distributorships to specialized treatment centers rather than promotion through the traditional primary care route. 2025 brought no changes to the weight-based (6.6 mg/kg) dosing of Ryplazim, and continued the requirement for specialized staff and facilities for administration. Future alliances and partnerships may broaden the geographic availability of treatment and decrease time to treatment in areas with restrictive reimbursement.

Establishing a visible market presence, like Kedrion for plasminogen, and other pipeline projects, provide the foundation for plasminogen to move beyond current market replacements. Manufacturing and clinical demands of plasminogen will mainly dictate the market by 2030.

Strategic Growth Opportunities in the Plasminogen Market

Maintain structure and content (including specific bullet points, spacing, headings, etc.) as exactly as possible. Do not revise or change companies mentioned in content. Use correct spelling for Lucintel and all other companies. Plasminogen market is poised for transformation beyond traditional indications and is gaining traction in the field of rare- diseases. Lucintel forecasts positive market outlook during the forecast period 2024-2026. Plasminogen has various potential indications and commercial opportunities that will be realized with adoption of specialized centers and strategic investments.

  • Plasminogen Replacement Therapy for Ligneous Conjunctivitis: A randomized trial was initiated in May 2025 with goal to enroll 20 subjects to investigate the safety and efficacy of plasminogen for ligneous conjunctivitis. Upon completion of the trial, plasminogen may gain indication for other ophthalmic conditions beyond replacement therapy.
  • Cases of Severe Type 1 Plasminogen Deficiency in Pediatrics: If cases of severe type 1 plasminogen deficiency in pediatrics are identified, it may reduce the prevalence of irreversible tissue damage. A 2026 prospective registry aims to recruit 30 pediatric cases of severe type 1 plasminogen deficiency.
  • Recombinant Plasminogen: A 2025 clinical program aims to determine the safety and efficacy of a recombinant plasminogen product in adult subjects with bleeding episodes associated with plasminogen deficiency. The sponsor expects to launch the product if they achieve equivalent product potency to currently available plasma-derived plasminogen.
  • Geographic Expansion: The main markets remain specialty markets, and there is a lot of potential in Europe, the Middle East and the Asia-Pacific region. By March 2025, a global distributor of rare disease drugs operated in over 50 countries. The next couple of years are expected to bring more regulatory changes and the formation of more partnerships which will facilitate the expansion of rare disease drug access, as well as the establishment of named-patient pathways.
  • Diagnostic-related Services: There are opportunities to provide related services such as testing and/or patient monitoring in connection with the patient's treatment. In October 2025, a laboratory network announced that it expected to be able to perform rare coagulation tests within the next 14 days. Other laboratory tests related to rare diseases may also be able to provide similar results. Laboratories may be able to set up similar arrangements with product manufacturers to perform testing and/or case finding.

There are a number of ways to sustain and enhance current revenue streams such as optimizing supply chain operations and adjusting pricing. However, in the long-term, there will be greater value in investing in funding research on the use of certain products for various rare conditions and aiding the development of reimbursement justifications for the use of such products.

Plasminogen Market Drivers and Challenges

Plasminogen is useful for treating some rare diseases and inflammatory conditions. With greater clinically recognized usage, the market is expected to grow. The ability of the market to grow is limited to the number of patients and the costs of production. From Lucintel viewpoint, the main barriers to commercialization are the availability of evidence, reimbursement, and reliability of the supply. Other barriers are regulatory approval and the balance of innovative therapies and affordability of the healthcare system. It is expected that in the next five years, the market will be combined by the efforts of the pharmaceutical companies to cover and reach the maximum number of patients that need their products.

The factors responsible for driving this market include :

  • Increasing Need for Rare Disease Treatments: Better identification of patients with plasminogen deficiency and associated mucosal, ocular and respiratory conditions promoted the usage of targeted plasminogen replacement therapies. As of September 2025, plasminogen replacement therapy has been published for use in patients with severely deficient plasminogen levels. The number of patients who are potentially benefitted from the therapy is not known, but in the next three to five years, with the implementation of rare disease programs by various countries, better awareness among the medical fraternity and improvement in diagnosis, the number of patients identified will increase.
  • Improvement in Biologics Manufacturing: There have been numerous improvements in manufacturing of plasminogen and other biologics. As of March 2026, several biologics companies adopted new methods for the manufacturing of biologics. These new methods, along with others, are expected to improve the consistency of plasminogen and other biologics in next three to five years. Further, improvements in manufacturing may allow companies to produce biologics for very small, rare patient populations.
  • Diagnostics: Plasminogen deficiencies are still commonly mistaken for other medical conditions. However, innovations in laboratory tests are improving the differential diagnosis of plasminogen deficiencies. In 2025, standardized plasminogen tests became more common in rare disease centers. Additionally, the use of combination plasminogen tests along with genetic analyses became more standard. Looking forward, it is expected that in the next 3-5 years, additional specialized tests and laboratories will become available, further improving diagnosis and timely treatment of plasminogen deficiencies. Improved diagnosis of rare diseases can alleviate the medical and emotional burden on patients. Improving access to diagnostic testing for rare diseases will facilitate the creation of disease-specific resources, especially for conditions that lack extensive health care and research infrastructure.
  • Pharmaceuticals: In 2025, numerous laws and policies across the globe improved the pharmaceutical industry's view of rare disease drugs and plasminogen replacement therapies. Additionally, in 2025, regulatory agencies stated their commitment to small patient populations and encouraged the development of rare disease drugs. The commitment of regulatory agencies is expected to improve the rare disease drug development process and create a positive environment for sponsors to address unmet needs. While manufacturing and clinical evidence will remain the responsibility of pharmaceutical companies, the committee expected the regulatory agencies would support and speed the rare disease drug development process.
    • New Product Development and Widened Clinical Application: Ongoing research on optimal dosing and alternate modes of delivery may allow the use of this product beyond the current indications. There is potential to utilize this product for the treatment of various inflammatory conditions and for the promotion of tissue healing. As of February 2026, studies focused on description of treatment in free-living-conditions and documentation of long-term outcomes. More innovations within the product may improve convenience, product satisfaction, and benefit to the patient. The development of new indications is highly dependent on the availability of supporting data.

The challenges facing this market include:

  • High Treatment Price and Lack of Reimbursement: Current methods for the treatment of these ultra-rare diseases involve the production of individualized and highly controlled biologics, resulting in very high costs. As of July 2025, the main focus of payers was on the benefits and durability of the treatment, as well as the expected impact on the payers' budget. It is expected that during the next 3 to 5 years, health care systems will perform a more rigorous economic assessment prior to reimbursement, resulting in limited access to the treatment. If this occurs, particularly in low income countries, the demand for the treatment will not be met.
  • Patient Population and Diagnostics: Plasminogen deficiency is rare and symptoms are similar to other more prevalent conditions. Therefore, many cases remain undiagnosed or misdiagnosed. As of November 2025, specialist networks reported the need for international collaboration and centralized testing to standardize diagnosis. Estimates suggest that in the next few years, the obstacles posed by the small and distant population of individuals with this condition will make it difficult to determine the demand and to transport the treatment to where it is needed. Undiagnosed cases can increase the disease's prevalence, and the difficulty in measuring the disease's true extent makes it challenging to evaluate the impact of treatment. Many affected individuals are in developing countries. There is little information about the prevalence and distribution of the disease. To reduce the prevalence of this condition, the development of national and international referral and consultation systems, as well as specialized training, is essential.
  • Supply and Demand Challenges: The transport and storage of biopharmaceutical products require special facilities, and an adequate supply of raw materials, posing a challenge to manufacturers. In 2026, companies anticipated disruptions in raw material supply. Dual sourcing of raw materials is common.

For the next 5 to 7 years, expectations of batch failures and other supply issues will likely result in significant disruptions in the market and further erode physician trust. Smaller markets, in particular, may create situations of high market concentration, since the presence of only a single supplier in the market would be economically unviable. As a result, reliability of supply may require the implementation of a combination of strategies including, supply chain management, logistics and inventory policies.

The market for plasminogen is likely to grow with improvement in diagnosis and policies that increase awareness and support for rare diseases. Additionally, the reliability of the biologics industry may facilitate the supply of other clot buster drugs. Newer and innovative drugs may facilitate wider use of existing drugs. Improvements in diagnostics may allow identification of previously undiagnosed cases. There will likely be continued increased interest in the development of plasminogen based drugs. The main challenges to the market development of plasminogen based drugs will likely be the price, especially public insurance reimbursement. Other challenges may include the unmet need, insufficient clinical data, and supply. Most likely, the market will be driven by the collaborative efforts of pharmaceutical companies, academia and the healthcare industry to provide more affordable and reliable drugs.

List of Plasminogen Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies plasminogen market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasminogen market companies profiled in this report include-

  • Kedrion S.p.A.
  • Grifols, S.A.
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG

Plasminogen Market by Segment

The study includes a forecast for the global plasminogen market by type, application, and region.

Plasminogen Market by Type [Value ($M) from 2019 to 2035]:

  • Intravenous Injection
  • Eye Drops

Plasminogen Market by Application [Value ($M) from 2019 to 2035]:

  • Ligneous Conjunctivitis
  • Diabetic Foot
  • Wound Healing
  • Others

Plasminogen Market by Region [Value ($M) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Plasminogen Market

Access to specialized manufacturing, and rare disease designations influence the plasminogen market. Around 2025-2027, companies will be focused on securing reliable sources of plasma in addition to purification processes and reimbursement. Lucintel has sweat the major constraints of market potential at this time.

  • Unites States: In 2021, the FDA approved the first Plasminogen Replacement Therapy (Ryplazim). With its designation as an Orphan Drug, the FDA will likely give Ryplazim, and similar products in the future, a pathway for expansion of its labeling. Other products in this category will likely face similar trajectories.
  • China: In September 2023, the Chinese National Medical Products Administration (NMPA) released an updated list of rare diseases (207), and will continue to provide designation pathways. Like Germany, increases in biopharmaceutical manufacturing will occur, and with the guidance of China's NMPA, technology and manufacturing partnerships will form for plasminogen.
  • Germany: The announcement by Biotest in September 2024 to significantly increase its plasma processing capacity in Europe, will fortify the regional supply of specialized plasma products.
  • India: The Indian Department of Pharmaceuticals launched the National Biopharma Mission in July 2017, with a target of 15000 million INR (approximately 2 billion USD) to foster research and develop manufacturing facilities for biologics. Investments in the biologics space will help further build the country's capacity in developing plasma protein therapies.
  • Japan: In April 2025, Japan's Ministry of Health, Labor and Welfare decided to include 341 diseases in its "Designated Intractable Diseases" list. Plasma-derived therapies are intended for rare diseases, and if Japan continues to add these therapies to its recognized list, plasminogen therapy is expected to be covered in the list and reimbursed in the next 3-5 years.

Features of the Global Plasminogen Market

  • Market Size Estimates: plasminogen market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: plasminogen market size by type, application, and region in terms of value ($B).
  • Regional Analysis: plasminogen market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the plasminogen market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plasminogen market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the plasminogen market by type (intravenous injection and eye drops), application (ligneous conjunctivitis, diabetic foot, wound healing, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Plasminogen Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Intravenous Injection : Trends and Forecast 2019 to 2035
  • 4.4 Eye Drops : Trends and Forecast 2019 to 2035

5. Global Plasminogen Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Ligneous Conjunctivitis : Trends and Forecast 2019 to 2035
  • 5.4 Diabetic Foot : Trends and Forecast 2019 to 2035
  • 5.5 Wound Healing : Trends and Forecast 2019 to 2035
  • 5.6 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Plasminogen Market by Region

7. North American Plasminogen Market

  • 7.1 Overview
  • 7.2 North American Plasminogen Market by Type
  • 7.3 North American Plasminogen Market by Application
  • 7.4 The United States Plasminogen Market
  • 7.5 Canadian Plasminogen Market
  • 7.6 Mexican Plasminogen Market

8. European Plasminogen Market

  • 8.1 Overview
  • 8.2 European Plasminogen Market by Type
  • 8.3 European Plasminogen Market by Application
  • 8.4 German Plasminogen Market
  • 8.5 French Plasminogen Market
  • 8.6 Italian Plasminogen Market
  • 8.7 Spanish Plasminogen Market
  • 8.8 The United Kingdom Plasminogen Market

9. APAC Plasminogen Market

  • 9.1 Overview
  • 9.2 APAC Plasminogen Market by Type
  • 9.3 APAC Plasminogen Market by Application
  • 9.4 Chinese Plasminogen Market
  • 9.5 Indian Plasminogen Market
  • 9.6 Japanese Plasminogen Market
  • 9.7 South Korean Plasminogen Market
  • 9.8 Indonesian Plasminogen Market

10. ROW Plasminogen Market

  • 10.1 Overview
  • 10.2 ROW Plasminogen Market by Type
  • 10.3 ROW Plasminogen Market by Application
  • 10.4 Middle Eastern Plasminogen Market
  • 10.5 South American Plasminogen Market
  • 10.6 African Plasminogen Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Plasminogen Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Kedrion S.p.A.
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Grifols, S.A.
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 CSL Behring
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Takeda Pharmaceutical Company Limited
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Octapharma AG
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 LFB S.A.
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 BioProduct Laboratory
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Green Cross Corp
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 China Biologic Products Holdings, Inc.
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Hualan Biological Engineering Inc.
    • Company Overview
    • Plasminogen Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Plasminogen Market
  • Figure 2.1: Usage of Plasminogen Market
  • Figure 2.2: Classification of the Global Plasminogen Market
  • Figure 2.3: Supply Chain of the Global Plasminogen Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Plasminogen Market
  • Figure 4.1: Global Plasminogen Market by Type in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global Plasminogen Market ($B) by Type
  • Figure 4.3: Forecast for the Global Plasminogen Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Intravenous Injection in the Global Plasminogen Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Eye Drops in the Global Plasminogen Market (2019-2035)
  • Figure 5.1: Global Plasminogen Market by Application in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global Plasminogen Market ($B) by Application
  • Figure 5.3: Forecast for the Global Plasminogen Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Ligneous Conjunctivitis in the Global Plasminogen Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Diabetic Foot in the Global Plasminogen Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Wound Healing in the Global Plasminogen Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Others in the Global Plasminogen Market (2019-2035)
  • Figure 6.1: Trends of the Global Plasminogen Market ($B) by Region (2019-2026)
  • Figure 6.2: Forecast for the Global Plasminogen Market ($B) by Region (2027-2035)
  • Figure 7.1: Trends and Forecast for the North American Plasminogen Market (2019-2035)
  • Figure 7.2: North American Plasminogen Market by Type in 2019, 2026, and 2035
  • Figure 7.3: Trends of the North American Plasminogen Market ($B) by Type (2019-2026)
  • Figure 7.4: Forecast for the North American Plasminogen Market ($B) by Type (2027-2035)
  • Figure 7.5: North American Plasminogen Market by Application in 2019, 2026, and 2035
  • Figure 7.6: Trends of the North American Plasminogen Market ($B) by Application (2019-2026)
  • Figure 7.7: Forecast for the North American Plasminogen Market ($B) by Application (2027-2035)
  • Figure 7.8: Trends and Forecast for the United States Plasminogen Market ($B) (2019-2035)
  • Figure 7.9: Trends and Forecast for the Mexican Plasminogen Market ($B) (2019-2035)
  • Figure 7.10: Trends and Forecast for the Canadian Plasminogen Market ($B) (2019-2035)
  • Figure 8.1: Trends and Forecast for the European Plasminogen Market (2019-2035)
  • Figure 8.2: European Plasminogen Market by Type in 2019, 2026, and 2035
  • Figure 8.3: Trends of the European Plasminogen Market ($B) by Type (2019-2026)
  • Figure 8.4: Forecast for the European Plasminogen Market ($B) by Type (2027-2035)
  • Figure 8.5: European Plasminogen Market by Application in 2019, 2026, and 2035
  • Figure 8.6: Trends of the European Plasminogen Market ($B) by Application (2019-2026)
  • Figure 8.7: Forecast for the European Plasminogen Market ($B) by Application (2027-2035)
  • Figure 8.8: Trends and Forecast for the German Plasminogen Market ($B) (2019-2035)
  • Figure 8.9: Trends and Forecast for the French Plasminogen Market ($B) (2019-2035)
  • Figure 8.10: Trends and Forecast for the Spanish Plasminogen Market ($B) (2019-2035)
  • Figure 8.11: Trends and Forecast for the Italian Plasminogen Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the United Kingdom Plasminogen Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the APAC Plasminogen Market (2019-2035)
  • Figure 9.2: APAC Plasminogen Market by Type in 2019, 2026, and 2035
  • Figure 9.3: Trends of the APAC Plasminogen Market ($B) by Type (2019-2026)
  • Figure 9.4: Forecast for the APAC Plasminogen Market ($B) by Type (2027-2035)
  • Figure 9.5: APAC Plasminogen Market by Application in 2019, 2026, and 2035
  • Figure 9.6: Trends of the APAC Plasminogen Market ($B) by Application (2019-2026)
  • Figure 9.7: Forecast for the APAC Plasminogen Market ($B) by Application (2027-2035)
  • Figure 9.8: Trends and Forecast for the Japanese Plasminogen Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Indian Plasminogen Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Chinese Plasminogen Market ($B) (2019-2035)
  • Figure 9.11: Trends and Forecast for the South Korean Plasminogen Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the Indonesian Plasminogen Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the ROW Plasminogen Market (2019-2035)
  • Figure 10.2: ROW Plasminogen Market by Type in 2019, 2026, and 2035
  • Figure 10.3: Trends of the ROW Plasminogen Market ($B) by Type (2019-2026)
  • Figure 10.4: Forecast for the ROW Plasminogen Market ($B) by Type (2027-2035)
  • Figure 10.5: ROW Plasminogen Market by Application in 2019, 2026, and 2035
  • Figure 10.6: Trends of the ROW Plasminogen Market ($B) by Application (2019-2026)
  • Figure 10.7: Forecast for the ROW Plasminogen Market ($B) by Application (2027-2035)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Plasminogen Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the South American Plasminogen Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the African Plasminogen Market ($B) (2019-2035)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Plasminogen Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Plasminogen Market (2026)
  • Figure 12.1: Growth Opportunities for the Global Plasminogen Market by Type
  • Figure 12.2: Growth Opportunities for the Global Plasminogen Market by Application
  • Figure 12.3: Growth Opportunities for the Global Plasminogen Market by Region
  • Figure 12.4: Emerging Trends in the Global Plasminogen Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Plasminogen Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Plasminogen Market by Region
  • Table 1.3: Global Plasminogen Market Parameters and Attributes
  • Table 3.1: Trends of the Global Plasminogen Market (2019-2026)
  • Table 3.2: Forecast for the Global Plasminogen Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global Plasminogen Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Plasminogen Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Plasminogen Market (2027-2035)
  • Table 4.4: Trends of Intravenous Injection in the Global Plasminogen Market (2019-2026)
  • Table 4.5: Forecast for Intravenous Injection in the Global Plasminogen Market (2027-2035)
  • Table 4.6: Trends of Eye Drops in the Global Plasminogen Market (2019-2026)
  • Table 4.7: Forecast for Eye Drops in the Global Plasminogen Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global Plasminogen Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Plasminogen Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Plasminogen Market (2027-2035)
  • Table 5.4: Trends of Ligneous Conjunctivitis in the Global Plasminogen Market (2019-2026)
  • Table 5.5: Forecast for Ligneous Conjunctivitis in the Global Plasminogen Market (2027-2035)
  • Table 5.6: Trends of Diabetic Foot in the Global Plasminogen Market (2019-2026)
  • Table 5.7: Forecast for Diabetic Foot in the Global Plasminogen Market (2027-2035)
  • Table 5.8: Trends of Wound Healing in the Global Plasminogen Market (2019-2026)
  • Table 5.9: Forecast for Wound Healing in the Global Plasminogen Market (2027-2035)
  • Table 5.10: Trends of Others in the Global Plasminogen Market (2019-2026)
  • Table 5.11: Forecast for Others in the Global Plasminogen Market (2027-2035)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Plasminogen Market (2019-2026)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Plasminogen Market (2027-2035)
  • Table 7.1: Trends of the North American Plasminogen Market (2019-2026)
  • Table 7.2: Forecast for the North American Plasminogen Market (2027-2035)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Plasminogen Market (2019-2026)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Plasminogen Market (2027-2035)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Plasminogen Market (2019-2026)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Plasminogen Market (2027-2035)
  • Table 7.7: Trends and Forecast for the United States Plasminogen Market (2019-2035)
  • Table 7.8: Trends and Forecast for the Mexican Plasminogen Market (2019-2035)
  • Table 7.9: Trends and Forecast for the Canadian Plasminogen Market (2019-2035)
  • Table 8.1: Trends of the European Plasminogen Market (2019-2026)
  • Table 8.2: Forecast for the European Plasminogen Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Type in the European Plasminogen Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Type in the European Plasminogen Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the European Plasminogen Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Application in the European Plasminogen Market (2027-2035)
  • Table 8.7: Trends and Forecast for the German Plasminogen Market (2019-2035)
  • Table 8.8: Trends and Forecast for the French Plasminogen Market (2019-2035)
  • Table 8.9: Trends and Forecast for the Spanish Plasminogen Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Italian Plasminogen Market (2019-2035)
  • Table 8.11: Trends and Forecast for the United Kingdom Plasminogen Market (2019-2035)
  • Table 9.1: Trends of the APAC Plasminogen Market (2019-2026)
  • Table 9.2: Forecast for the APAC Plasminogen Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Plasminogen Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Plasminogen Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Plasminogen Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Plasminogen Market (2027-2035)
  • Table 9.7: Trends and Forecast for the Japanese Plasminogen Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Indian Plasminogen Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Chinese Plasminogen Market (2019-2035)
  • Table 9.10: Trends and Forecast for the South Korean Plasminogen Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Indonesian Plasminogen Market (2019-2035)
  • Table 10.1: Trends of the ROW Plasminogen Market (2019-2026)
  • Table 10.2: Forecast for the ROW Plasminogen Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Plasminogen Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Plasminogen Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Plasminogen Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Plasminogen Market (2027-2035)
  • Table 10.7: Trends and Forecast for the Middle Eastern Plasminogen Market (2019-2035)
  • Table 10.8: Trends and Forecast for the South American Plasminogen Market (2019-2035)
  • Table 10.9: Trends and Forecast for the African Plasminogen Market (2019-2035)
  • Table 11.1: Product Mapping of Plasminogen Suppliers Based on Segments
  • Table 11.2: Operational Integration of Plasminogen Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Plasminogen Revenue
  • Table 12.1: New Product Launches by Major Plasminogen Producers (2019-2026)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Plasminogen Market